| 2025 | 2024 | 2023 | 2022 | 2021 | 2013 | 2012 | 2011 | 2009 | 2008 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 2,6 k € | -98.2% | 145,6 k € | +2254.9% | -6,8 k € | -72.9% | -3,9 k € | +41.8% | -6,7 k € | +96.6% | -198,2 k € | +18.6% | -243,5 k € | +16.4% | -291,3 k € | +40.7% | -491,3 k € | -126.4% | -217,0 k € | |
| EBITDA | 1,8 k € | +106.3% | -28,7 k € | -323.3% | -6,8 k € | -73.3% | -3,9 k € | +44.7% | -7,1 k € | +98.9% | -638,4 k € | +5.6% | -675,9 k € | +29.8% | -962,8 k € | -40.3% | -686,5 k € | -85.5% | -370,1 k € | |
| Operating profit | 1,8 k € | +106.3% | -28,7 k € | +76.8% | -123,5 k € | -1.5% | -121,7 k € | +3.1% | -125,6 k € | +85.2% | -850,3 k € | +5.2% | -896,8 k € | +22.9% | -1,2 M € | -39.2% | -835,5 k € | -65.3% | -505,4 k € | |
| Profit/loss | 1,6 k € | +105.6% | -28,9 k € | +78.2% | -132,5 k € | -1.7% | -130,3 k € | +2.5% | -133,6 k € | +85.5% | -924,2 k € | -0.8% | -916,7 k € | +39.1% | -1,5 M € | -81.1% | -831,0 k € | -87.0% | -444,3 k € | |
| Equity | 2,1 k € | +331.5% | 489,4 € | -98.3% | 29,4 k € | -81.9% | 161,9 k € | -44.6% | 292,2 k € | -26.9% | 399,6 k € | -69.8% | 1,3 M € | -24.0% | 1,7 M € | -51.4% | 3,6 M € | +32.3% | 2,7 M € | |
| Total assets | 2,1 k € | +331.5% | 489,4 € | -99.7% | 185,6 k € | -40.2% | 310,1 k € | -28.9% | 435,9 k € | -77.5% | 1,9 M € | +10.6% | 1,8 M € | -29.4% | 2,5 M € | -34.0% | 3,8 M € | +32.9% | 2,8 M € | |
| Cash | 1,8 k € | +771.7% | 210,5 € | -95.4% | 4,6 k € | -57.7% | 10,9 k € | -44.0% | 19,4 k € | -94.2% | 336,3 k € | +464.2% | 59,6 k € | -72.7% | 218,6 k € | -89.1% | 2,0 M € | +67.7% | 1,2 M € | |
| Debts | — | 0,0 € | -100.0% | 101,0 k € | -0.8% | 101,7 k € | +0.2% | 101,5 k € | -93.1% | 1,5 M € | +252.0% | 416,8 k € | -42.6% | 726,1 k € | +336.8% | 166,2 k € | +90.9% | 87,1 k € | ||
| Staff | 0 | 0 | — | — | — | 5 | 5 | 6 | 3,6 | 2,5 | ||||||||||
Public limited company · Leuven · incorporated on 03/10/2007 · 0,0 ETP
Public limited company profitable and well capitalised. Cash position rising (+771.7%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
Formac Pharmaceuticals is a Public limited company incorporated in 2007. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Leuven.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette